JP2024542159A5 - - Google Patents
Info
- Publication number
- JP2024542159A5 JP2024542159A5 JP2024527078A JP2024527078A JP2024542159A5 JP 2024542159 A5 JP2024542159 A5 JP 2024542159A5 JP 2024527078 A JP2024527078 A JP 2024527078A JP 2024527078 A JP2024527078 A JP 2024527078A JP 2024542159 A5 JP2024542159 A5 JP 2024542159A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- determination region
- containing seq
- chain complementarity
- complementarity determination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163275890P | 2021-11-04 | 2021-11-04 | |
| US63/275,890 | 2021-11-04 | ||
| PCT/US2022/048887 WO2023081317A2 (en) | 2021-11-04 | 2022-11-03 | Treatment of cancer with nk cells and multispecific engagers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024542159A JP2024542159A (ja) | 2024-11-13 |
| JP2024542159A5 true JP2024542159A5 (https=) | 2025-11-12 |
Family
ID=86242049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527078A Pending JP2024542159A (ja) | 2021-11-04 | 2022-11-03 | Ｎｋ細胞と多重特異性エンゲージャーとによるがんの処置 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240424099A1 (https=) |
| EP (1) | EP4426350A4 (https=) |
| JP (1) | JP2024542159A (https=) |
| KR (1) | KR20240107147A (https=) |
| CN (1) | CN118613271A (https=) |
| AU (1) | AU2022380926A1 (https=) |
| CA (1) | CA3237016A1 (https=) |
| IL (1) | IL312555A (https=) |
| WO (1) | WO2023081317A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3567049A4 (en) | 2016-12-28 | 2020-08-26 | Green Cross Lab Cell Corporation | CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME |
| EP3633029A4 (en) | 2017-05-26 | 2021-06-09 | Green Cross Lab Cell Corporation | METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| KR102774451B1 (ko) | 2017-11-14 | 2025-02-28 | 앱클론(주) | 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체 |
| AU2019381526B2 (en) | 2018-11-14 | 2023-02-23 | Green Cross Lab Cell Corporation | Method for culturing cord blood-derived natural killer cells using transformed T-cells |
| JP2024540347A (ja) * | 2021-11-09 | 2024-10-31 | ウーゲン，インコーポレイテッド | 記憶ｎｋ細胞と抗癌性二重特異性分子とによる組み合わせ癌療法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2650730A1 (en) * | 2006-04-27 | 2007-11-08 | Pikamab, Inc. | Methods and compositions for antibody therapy |
| EP3184109B1 (en) * | 2009-12-29 | 2020-11-18 | Gamida-Cell Ltd. | Methods for enhancing natural killer cell proliferation and activity |
| JP7237449B2 (ja) * | 2015-02-27 | 2023-03-13 | アイセル・ジーン・セラピューティクス・エルエルシー | 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| LT3292153T (lt) * | 2015-05-04 | 2019-11-11 | Affimed Gmbh | Cd30xcd16a antikūno derinys su antagonistiniu antikūnu prieš pd-1 skirtas terapijai |
| HRP20240821T1 (hr) * | 2018-08-27 | 2024-09-27 | Affimed Gmbh | Stanice nk čuvane zamrzavanjem, koje su prethodno ubačene uz protutijelni konstrukt |
| EP4045539A4 (en) * | 2019-10-17 | 2024-03-13 | Fate Therapeutics, Inc. | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
-
2022
- 2022-11-03 CN CN202280087592.8A patent/CN118613271A/zh active Pending
- 2022-11-03 US US18/707,276 patent/US20240424099A1/en active Pending
- 2022-11-03 EP EP22890795.2A patent/EP4426350A4/en active Pending
- 2022-11-03 IL IL312555A patent/IL312555A/en unknown
- 2022-11-03 KR KR1020247018559A patent/KR20240107147A/ko active Pending
- 2022-11-03 AU AU2022380926A patent/AU2022380926A1/en active Pending
- 2022-11-03 CA CA3237016A patent/CA3237016A1/en active Pending
- 2022-11-03 WO PCT/US2022/048887 patent/WO2023081317A2/en not_active Ceased
- 2022-11-03 JP JP2024527078A patent/JP2024542159A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024542159A5 (https=) | ||
| AU2022204601B2 (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| KR102363191B1 (ko) | 면역치료용 조성물 및 방법 | |
| CA3019650C (en) | Chimeric receptors and methods of use thereof | |
| DK1648507T3 (en) | PROCEDURES AND COMPOSITIONS FOR INCREASING THE EFFECTIVENESS OF THERAPEUTIC ANTIBODIES USING COMPOUNDS THAT POTENTATE NK CELLS | |
| CN113383071A (zh) | 用于t细胞工程化的组合物和方法 | |
| JP2021532829A (ja) | ガンマ−デルタｔ細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法 | |
| JP2025106512A (ja) | 調節性ｔ細胞及びその使用 | |
| AU2025203410A1 (en) | Anti-TCR antibody molecules and uses thereof | |
| JP2023519099A5 (https=) | ||
| JP2024527559A5 (https=) | ||
| JP2022512917A5 (https=) | ||
| JP2013014587A (ja) | Ｔ細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法 | |
| CA3134308A1 (en) | Rituximab-resistant chimeric antigen receptors and uses thereof | |
| JP2023519098A5 (https=) | ||
| JP2024513958A5 (https=) | ||
| US20250171731A1 (en) | Methods of manufacturing allogeneic car t cells | |
| US20230293685A1 (en) | Selection of improved tumor reactive t-cells | |
| CA3202483A1 (en) | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors | |
| JP2021525068A (ja) | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ２表面発現の遮断およびキメラ抗原受容体の発現 | |
| JP2021525067A (ja) | Ｔ細胞悪性腫瘍の免疫療法のためのキメラ抗原受容体およびｃｄ２の遺伝子編集 | |
| KR20230007384A (ko) | 치료 방법 | |
| US20240216430A1 (en) | Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof | |
| RU2816370C2 (ru) | Устойчивые к ритуксимабу химерные антигенные рецепторы и пути их применения | |
| JP2026502532A (ja) | Ｔ細胞及びｎｋ細胞悪性腫瘍の免疫療法のためのｃｄ８発現及びキメラ抗原受容体の遮断 |